Nexletol (bempedoic acid) can cause side effects that range from mild to serious. More common side effects include muscle spasms, back pain, and anemia. If side effects from Nexletol become ...

12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL ...

ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to ...

Net product sales grew 46.2% year over year during the first nine months of 2024, owing to prescription growth volumes of Nexletol and Nexlizet. The positive trend is expected to continue in 2025.

Esperion Therapeutics has announced a licensing agreement with Neopharm Israel, granting Neopharm exclusive rights to commercialize its products NEXLETOL® and NEXLIZET® in Israel, Gaza ...

The firm pointed out the company's marketing of NEXLETOL and NEXLIZET, which are oral ATP-citrate lyase inhibitors used for lowering LDL cholesterol and reducing cardiovascular risk. Currently ...